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BACKGROUND: The pharmacological treatment of migraine may be acute or preventive. Frequent, severe and long-
lasting migraine attacks require prophylaxis. Multiple threads of research over the last 15 years have led to the concept that
migraine is generated from a hyperexcitable brain. A variety of causes for hyperexcitability of the brain in migraine have
been suggested. These causes include low cerebral magnesium levels, mitochondrial abnormalities, dysfunctions related to
increased nitric oxide or the existence of a P/Q type calcium channelopathy. The better knowledge about migraine
pathophisiology led us to discuss new treatment options.
OBJECTIVES: The aim of the present study is to present an evidence-based review of some new drugs or some agents
that even though available for a long time, are not frequently used.
METHODS/RESULTS: We present a review of anticonvulsants with various mechanisms of action such as lamotrigine,
gabapentin, topiramate, tiagabine, levetiracetam and zonisamide. We also review natural products, like riboflavin and
magnesium, botulinum toxin A, a specific CGRP antagonist and the anti-asthma medication montelukast, with
pathophysiological discussion.
CONCLUSIONS: We aimed to present an update of newer or less frequently used preventive migraine therapies, drugs
that might reduce the burden and the costs of a disease that should be considered as a public health problem all around the
world.
DESCRIPTORS: Migraine. Preventive treatment. Prophylactic treatment. Update.
INTRODUCTION
Multiple threads of research over
the last 15 years have led to the con-
cept that migraine is generated from a
hyperexcitable brain1. In spite of the
fact that we are not sure whether mi-
graine is generated in the cortex or
brainstem, one possible scenario
would include a cascade of events be-
ginning with cortical activation, fol-
lowed by brainstem activation, leading
to activation of ascending and de-
scending pathways, with initiation of
a perimeningeal vasodilatation and
neurogenic inflammation2-4. A variety
of causes for hyperexcitability of the
brain in migraine have been suggested.
These include low cerebral magnesium
levels, mitochondrial abnormalities,
dysfunctions related to increased nitric
oxide or the existence of a P/Q type
calcium channelopathy5-8.
Effective migraine treatment be-
gins with making an accurate diagno-
sis, ruling out alternate causes, and ad-
dressing the headache’s impact on the
patient. The treatment involves non-
pharmacologic behavioral and physi-
cal measures and pharmacotherapy.
The pharmacological treatment of mi-
graine may be acute or preventive, re-
membering that they are not mutually
exclusive. A significant number of pa-
tients will benefit from a combined ap-
proach.
The aim of the present study is to
present an evidence-based review of
some new drugs or some agents that
even though available for a long time,
are not frequently used.
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PREVENTIVE TREATMENT
Preventive medications are usually
taken in a daily basis, to reduce the fre-
quency, duration or severity of attacks.
Some good reasons for migraine pre-
vention are: 1 – Frequently recurring
migraine that significantly interferes
with the patient’s daily routine, despite
using an appropriate acute treatment;
2 – Failure, contraindication or ad-
verse events when using acute medi-
cations; 3 – Overuse of acute medica-
tions; 4 – Patient preference.
The major medication groups for
preventive migraine treatment include
B-adrenergic blockers, antidepressants
of all types, calcium channel antago-
nists, serotonin antagonists and
anticonvulsivants. We will focus on
new and not frequently used options.
1 – Natural Products
A – Vitamin B2 (riboflavin)
A mitochondrial dysfunction re-
sulting in impairment of oxygen me-
tabolism and low cellular energy lev-
els may play a role in migraine
pathogenesis7. Riboflavin (vitamin
B2) is the precursor of flavin mononu-
cleotide and flavin adenine dinucle-
otide, which are required for the activ-
ity of flavoenzymes involved in the
electron transport chain in the mito-
chondria of the cells9. Given to pa-
tients with mitochondriopathies, ribo-
flavin improved some clinical and
biochemical parameters10.
A double blind study of large
doses of riboflavin (400 mg / day)
compared with placebo in migraine
prevention showed that riboflavin
was significantly superior at reducing
the attack frequency, headache inten-
sity and other indexes after three
months of therapy. The proportion of
patients that improved at least 50%
was 15% for placebo and 59% for ri-
boflavin. No serious adverse events
were reported11.
B – Magnesium
As mentioned above, low levels of
magnesium are probably associated
with the cascade of events that might
trigger migraine. It seems reasonable
that this ion had been studied in the
preventive and acute treatments of mi-
graine.
Some studies have demonstrated
low intracellular magnesium in the
migrainous brain12-13. Two studies
evaluated the effects of magnesium
supplementation in the preventive
treatment of migraine, with
contradictories results. The first one
enrolled 81 patients in a placebo-con-
trolled study. The attack frequency was
reduced by 41.6% in the magnesium
group and by 15.8% in placebo group.
Adverse events were diarrhea and gas-
tric irritation14. The other study evalu-
ated 69 patients and was discontinued
because they were not able to identify
benefits in magnesium group. These
patients had severe diarrhea and may
not have absorbed the magnesium
from the gastrointestinal tract15.
The studies differed in the amount
of magnesium (24 vs. 20 mmol) and in
the salt (dicitrate vs. aspartate). These
differences may explain at least part of
the contradictory conclusions. Despite
these conflicting results, many clini-
cians believe that magnesium can be
useful in some patients. It can be ta-
pered from 64 mg bid (Slow-Mag) to
128 mg bid, or be used in higher doses
of other salts at a level of 200 mg bid
or 400 mg QD.
2 – Antiepileptic Drugs
C – Gabapentin
Gabapentin is an anticonvulsant
agent structurally related to the inhibi-
tory neurotransmitter Gamma-
aminobutyric acid (GABA) 16. Although
gabapentin was developed as a struc-
tural analog of GABA that would pen-
etrate the blood-brain barrier (unlike
GABA) and mimic the action of GABA
at inhibitory neuronal synapses, the
drug has no direct GABA-mimetic ac-
tion and its precise mechanism of ac-
tion has not been elucidated17.
Gabapentin seems to be an anti-
convulsant particularly effective in
treating chronic pain syndromes. A re-
cent double-blind trial that used
gabapentin from 1800 mg to 2400 mg
per day showed this drug to be supe-
rior to placebo in reducing frequency
and intensity of pain18. Gabapentin
was effective in 46% of patients,
against 14% of placebo that had failed
to other therapies. The most common
adverse events of this drug are dizzi-
ness, drowsiness and weight gain.
D – Topiramate
Topiramate is a structurally unique
anticonvulsant, rapidly and almost
completely absorbed. It is eliminated
predominantly unchanged in the urine.
This drug differs structurally from other
currently available anticonvulsant
agents19. The spectrum of topiramate’s
anticonvulsant activity resembles that
of carbamazepine and phenytoin19, al-
though differences in certain animal
models have been observed and addi-
tive effects appear to occur when the
drug is combined with these anticon-
vulsants20. It has been associated with
weigh loss, not weight gain, which is a
common reason to discontinue preven-
tive medication. Almost all patients
complain about slight peripheral
paresthesias in the hands and feet. A
rare side effect is cognitive dysfunc-
tion, fully reversed with therapy discon-
tinuation.
One study that used topiramate in
migraine and chronic daily headache
reported one third of the patients with
significant improvement, one third
with moderate improvement and an-
other third without improvement21.
 A second double-blind study
showed that topiramate produced more
than 50% decrease in pain in 46.7%
of patients vs. 6.7% of placebo. A third
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double blind study, using a mean
topiramate dose of 125 mg (range 25
to 200 mg) also showed a significant
improvement against placebo. Topira-
mate must be gradually increased from
a 15 or 25 mg per day dose in order to
avoid side effects22.
E – Tiagabine
Although the precise mechanism of
action of tiagabine is unknown, the
drug enhances inhibitory neurotrans-
mission mediated by GABA23.
Tiagabine increases the amount of
GABA available in extracellular spaces
of the globus pallidus, ventral
pallidum, and substantia nigra suggest-
ing a GABA-mediated anticonvulsant
mechanism of action24.
Tiagabine is an antiepileptic drug
still poorly studied as a preventive
migrainous option. An open-label
clinical trial with 41 patients, all pre-
viously treated with divalproex and
discontinued due to lack of efficacy or
adverse events, showed that 5 patients
had remission and 33 had significant
reduction of the frequency of attacks.
The mean dose was 10 mg /day25.
F – Levetiracetam
Levetiracetam, a pyrrolidine de-
rivative, is an anticonvulsant agent
that is structurally unrelated to other
currently available anticonvulsants26.
The mechanism of anticonvulsant ac-
tion of levetiracetam is unknown and
does not appear to be related to any
known mechanisms involved in
excitatory or inhibitory neurotrans-
mission27. In animal models, levetira-
cetam conferred no protection against
single seizures induced by electrical
current or different chemoconvulsants
and offered only limited protection in
submaximal stimulation and threshold
tests. Protection was observed against
secondarily generalized activity from
focal seizures induced by two chemo-
convulsants known to induce seizures
that mimic some features of human
complex partial seizures with second-
ary generalization. Levetiracetam also
showed inhibitory properties in the
kindling model in rats, another model
of human complex partial seizures27.
Levetiracetam is not extensively
metabolized in humans, with 66% of
an administered dose excreted un-
changed in urine. About 24% of an ad-
ministered dose is metabolized to an
inactive metabolite by enzymatic hy-
drolysis of the acetamide group, which
does not depend on hepatic cyto-
chrome P-450 (CYP) isoenzymes27.
Using the rational that virtually all
commercially available anticonvulsi-
vants have shown efficacy in the treat-
ment of migraine, this drug has re-
cently been evaluated for this use. One
first open study with 30 patients that
had previously failed to at least two
other agents has been levetiracetam
added to their current preventive treat-
ment. Fourteen (46.7%) reported more
than 50% reduction in their migraine
frequency and intensity with 3 months
of active therapy. Dosage was adjusted
from 2,000 to 4,500 mg per day in two
or three doses. The authors concluded
that levetiracetam could be an option
in the treatment of refractory head-
aches28.
A second study, with the same de-
sign, reported similar conclusions. The
adverse event rates (no serious events
were reported) was 16.1%29.
G – Zonisamide
Zonisamide, an anticonvulsivant
recently introduced in the US, has a
unique combination of pharmacologic
actions: it inhibits voltage-gated Na+
channels and also blocks T—type cal-
cium channels30. Both of these mecha-
nisms may play a role in headache and
pain modulation, possibly via neuro-
nal stabilization. An open study was
performed on 27 patients, all with re-
fractory headaches, that received
zonisamide in addition to the preven-
tive treatment. One hundred mg was
given in the evening every third day
and then increased every 2 weeks un-
til a maximum dose of 600 mg a day
in 4 or 5 doses. Six (22.2%) patients
reported a 65% or better decrease in
frequency of migraines; 8 (29.6%) had
from 25% to 50% . Four (14.8%) pa-
tients stopped due to side-effects30 . A
second study used from 10 mg to 400
mg, reported similar efficacy profiles.
Paresthesias, fatigue, anxiety and
weight loss were the most frequent ad-
verse events reported31.
3 - Miscellaneous
H – Montelukast sodium
Leukotrienes and other inflamma-
tory mediators have been implicated in
the inflammatory cascade believed to
be associated with the pathophysiology
of migraine32. The name “leukotriene”
is derived both from the parent mol-
ecule, which was originally isolated
from leukocytes, and from its three
double-bond carbon backbone or triene
structure. Both prostaglandins and
leukotrienes are derived from the me-
tabolism of arachidonic acid, with
prostaglandins coming off the
cyclooxygenase pathway and leuko-
trienes derived via the enzyme 5-
lipoxygenase. Both prostaglandins and
leukotrienes mediate inflammatory re-
sponses33.
Nonsteroidal anti-inflammatory
agents have been used widely in the
treatment of migraine. It is reasonable
to think that medications that could an-
tagonize leukotriene functions could be
effective in migraine prevention. The
clinical observation of a decrease in
migraine frequency in patients with
comorbid asthma taking montelukast,
a specific D4 leukotriene receptor an-
tagonist, lead to the first open study, by
Sheftell et al.34, using montelukast so-
dium, 10 or 20 mg, in the prevention
of migraine. In this study montelukast
was extremely well tolerated, and no
adverse events were reported by any of
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the patients. Fifty-three percent showed
a reduction greater than 50% (P<.025)
in the frequency of severe attacks, with
41% showing a reduction greater than
60%. Responders, including modest re-
sponders, rated the drug as excellent.
The authors concluded that
montelukast shows potential as an ef-
fective, well-tolerated prophylactic
agent in migraine, double-blinded, pla-
cebo-controlled studies being neces-
sary. Recently, a poster was presented
at the 2001 International Headache
Congress showing the efficacy and
safety of this drug in children and ado-
lescents35.
I – Lisinopril
Lisinopril (LSN) is a dicarboxyl-
containing angiotensin converting en-
zyme (ACE) inhibitor proven efficient
to treat hypertension and heart failure.
It is structurally related to enalapril
and it was the third ACE inhibitor ap-
proved for use in the United States. In
vitro, LSN is slightly more potent than
enalaprilat, an injectable ACE inhibi-
tor, even though it is its lysine analog.
After oral administration LSN is
slowly, variably and incompletely
(30%) absorbed; peak plasma concen-
trations are achieved in about 7 hours.
It is cleared as the intact compound by
the kidney, and its half-life in plasma
is about 12 hours. LSN does not accu-
mulate in tissues. The suggested oral
doses for hypertension ranges from 5
to 40 mg daily (in single or divided
doses), with 10 mg daily being appro-
priate for the initiation of therapy36,37.
LSN was studied in a randomized,
placebo-controlled, crossover trial38
for the prophylactic treatment of mi-
graine. The study involved sixty pa-
tients, aged 19-59 years, that presented
two to six migraine attacks in a 4-week
run-in phase. In the 47 participants
who completed the study, hours with
headache, days with headache, days
with migraine, and headache severity
index were significantly reduced by
20%, 17%, 21%, and 20% respec-
tively, with LSN compared with pla-
cebo. Days with migraine were fewer
by at least 50% in 14 patients for ac-
tive treatment versus PCB. LSN was
well tolerated and side effects ob-
served were those know to be associ-
ated with ACE inhibitors. Eight pa-
tients reported coughing (vs. 3 in pla-
cebo group, 3 patients of LSN group
withdrew due to coughing), 3 reported
fatigue (vs. 3 in placebo group), 7 pre-
sented dizziness (vs. 4 in PCB) and 3
reported tendency to faint (vs. 0 in
PCB) (total side effects 24 LSN pa-
tients vs. 13 PCB patients, p=0.07).
LSN has various pharmacological
effects that may be relevant in mi-
graine. In addition to blocking the
conversion of angiotensin I to angi-
otensin II, it also alters the sympathetic
activity, inhibits free radical activity,
increases prostacyclin synthesis, and
blocks the degradation of bradykinin,
encephalin, and substance P39. Of par-
ticular relevance to LSN efficacy in
migraine prevention, may be the recent
finding that migraine without aura
seems to be more common in people
with the angiotensin converting en-
zyme DD gene, and the fact that
migraineurs with this gene also have
higher angiotensin converting enzyme
activity and a higher frequency of at-
tacks than other migraine sufferers39.
 J – Botulinum toxin
Botulinum toxin type A injections
often reduce the pain associated with
conditions such as cervical dystonia,
achalasia, rectal fissures, and
myofascial pain syndrome40. Some
open-label, noncontrolled studies of
botulinum toxin type A suggested
benefits for patients with migraine. A
recent double-blind study40, evaluat-
ing 25-U and 75-U doses showed that,
compared with vehicle treatment, sub-
jects in the 25-U botulinum toxin type
A treatment group showed signifi-
cantly fewer migraine attacks per
month, a reduced maximum severity of
migraines, a reduced number of days
using acute migraine medications, and
reduced incidence of migraine-associ-
ated vomiting. Both the 25-U and 75-
U botulinum toxin type A groups were
significantly better than the vehicle
group on subject global assessment.
Botulinum toxin A treatment was well
tolerated, with only the 75-U treatment
group exhibiting a significantly
higher rate of treatment-related adverse
events than vehicle. They concluded
that pericranial injection of botulinum
toxin type A, 25 U, was found to be a
safe treatment that significantly re-
duced migraine frequency, migraine
severity, acute medication usage, and
associated vomiting. It is symmetri-
cally injected into glabellar, frontalis
and temporalis muscles and eventually
in other pericranial regions. The ma-
jor side effect is mild ptosis that usu-
ally stays less than one week. Injections
should be repeated every 3 months40.
Clinical impression shows that some
patients have a great response with this
treatment, while other patients show
practically absence or results.
4 – Future Possibilities
K – Calcitonin gene-related peptide
antagonism.
This kind of potentially promising
migraine treatment is undergoing pre-
clinical research. Calcitonin gene-re-
lated peptide (CGRP) is one of the
most potent endogenous vasodilators
known. This peptide is increased dur-
ing migraine attacks and has been im-
plicated in the pathogenesis of mi-
graine headache. Its first small mol-
ecule selective CGRP antagonist has
been synthesized: BIBN4096BS. In
vitro, this compound is extremely po-
tent at primate CGRP receptors exhib-
iting an affinity (Ki) for human CGRP
receptors. In an in vivo model,
BIBN4096BS in doses between 1 and
30 micrograms kg-1 (i.v.) inhibited the
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effects of CGRP, released by stimula-
tion of the trigeminal ganglion, on fa-
cial blood flow in marmoset mon-
keys41.
CONCLUSIONS
Analysis of preventive migraine
therapies pose methodological is-
sues42. Many early studies done prior
to the International Headache Society
Classification43 used loose criteria to
define migraine. Many preventives
studies were poorly performed, did not
provide adequate details of statistical
methods or were reported only as ab-
stracts, making proper analysis of the
evidence difficult. Despite some of
these drawbacks persisting until nowa-
days, we aimed to present an update
of newer or less frequently used pre-
ventive migraine therapies, drugs that
might reduce the burden and the costs
of a disease that should be considered
as a public health problem all around
the world.
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293-298 2002.
INTRODUÇÃO: O tratamento
farmacológico da migrânea pode ser
dividido em agudo e preventivo. Cri-
ses de migrânea severas, de longa du-
ração e incapacitante requerem profi-
laxia. Múltiplas linhas de pesquisa ao
longo dos últimos 15 anos sedimen-
taram o conceito de que a migrânea é
gerada a partir de um cérebro hiper-
excitável. Variadas causas para essa
hiperexcitabilidade têm sido sugeridas
e incluem baixo nível de magnésio ce-
rebral, anormalidades mitocondriais,
disfunções relacionadas ao óxido
nítrico e a existência de distúrbios nos
canais de cálcio do tipo P/Q. O melhor
conhecimento sobre a fisiopatologia
da migrânea nos permite discutir no-
vas opções terapêuticas.
OBJETIVOS: O objetivo do pre-
sente estudo é apresentar revisão ba-
seada em evidências de novos agentes
e outros que, embora disponíveis há
mais tempo, não são freqüentemente
utilizados, com considerações fisio-
patológicas.
MÉTODOS/RESULTADOS: Se-
rão revistos anticonvulsivantes com
vários mecanismos de ação, como
gabapentina, lamotrigina, topiramato,
tiagabina, levetiracetam e zonisamida.
Serão revistos também produtos natu-
rais, como riboflavina e magnésio, to-
xina botulínica do tipo A, um antago-
nista CGRP específico e uma nova op-
ção para o tratamento da asma, o
montelukast.
CONCLUSÕES: Objetivamos
apresentar artigo de atualização em
opções novas ou não freqüentemente
utilizadas no tratamento preventivo da
migrânea, drogas que podem reduzir o
fardo e os custos de uma doença que
deve ser considerada um problema de
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